Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Iovance Biotherapeutics, Inc. Common Stock

IOVA

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Last trade $7.43
Day change -$0.12 (-1.59%)
Day range $7.26 – $7.76
Volume 6,471,055
Market cap $3.49B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.49B
Price / earnings
—
Price / book
4.3×
Price / sales
9.22×
EV / sales
9.06×
EV / EBITDA
-17.81×

Profitability

Earnings per share
-$0.48
Return on assets
-22.25%
Return on equity
-27.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.2×
Quick ratio
4.67×
Cash ratio
0.55×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$216.06M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IOVA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$121.47M$99.31M$71.43M$86.77M$67.46M$59.95M$49.32M$73.69M
Cost of revenue$48.03M$43.6M$42.5M$43.11M$38.48M$48.88M$42.72M$37.79M
Gross profit$73.44M$55.72M$28.93M$43.66M$28.98M$11.07M$6.61M$35.91M
Selling, general and administrative$38.58M$39.27M$38.95M$36.4M$34.56M$37.57M$43.8M$42.32M
Research and development$49.34M$58.85M$62.49M$71.2M$75.17M$77.93M$75.97M$71.01M
Total operating expenses$97.41M$107.62M$109.98M$117.12M$123.88M$124.85M$127.83M$122.48M
Operating income-$23.97M-$51.91M-$81.04M-$73.46M-$94.9M-$113.77M-$121.22M-$86.58M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$21.66M-$48.69M-$79.71M-$71.72M-$93.66M-$109.67M-$118M-$77M
Income taxes$614K-$1.37M-$665K$184K-$2.41M$1.99M-$1.84M$1.56M
Net income-$22.27M-$47.32M-$79.05M-$71.9M-$91.25M-$111.66M-$116.16M-$78.56M
Net income attributable to common shareholders-$22.27M-$47.32M-$79.05M-$71.9M-$91.25M-$111.66M-$116.16M-$78.56M
EBITDA-$14.47M-$42.41M-$72.5M-$63.53M-$81.16M-$104.42M-$113.16M-$72.58M
Basic earnings per share-$0.05-$0.11-$0.19-$0.18-$0.25-$0.33-$0.36-$0.26
Diluted earnings per share-$0.05-$0.11-$0.19-$0.18-$0.25-$0.33-$0.36-$0.26

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress

Iovance Biotherapeutics (IOVA) reported Q3 2026 revenues of $121.5M, surpassing estimates, with Amtagvi sales growing 77% to $102M. The company reaffirmed full-year revenue guidance of $410-$420M, highlighted improving gross margins at 60%, and advanced its pipeline with lung cancer and sarcoma trials targeting regulatory submissions in 2027-2029. Management expects cash resources to support operations into 2029.

Zacks Investment Research

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised

Amneal Pharmaceuticals (AMRX) reported Q3 2026 adjusted EPS of 26 cents, beating consensus estimates of 24 cents, with revenues of $862.6 million up 10% year-over-year. The company raised its 2026 guidance for net revenue, adjusted EBITDA, and adjusted EPS, citing strong growth in Affordable Medicines and Specialty segments. Recent FDA approvals and the acquisition of Kashiv BioSciences strengthen its biosimilar portfolio, with launches expected through 2029.

Zacks Investment Research

Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.

Zacks Investment Research

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

Iovance Biotherapeutics is projected to report Q3 2026 revenues of $117.7 million with a loss of 9 cents per share, expected to beat earnings estimates. Amtagvi is anticipated to drive ~$95 million in sales, while Proleukin could contribute ~$22 million. The company has a positive Earnings ESP of +44.44% and Zacks Rank #2, with investors awaiting pipeline updates on combination studies for melanoma and other cancer indications.

Zacks Investment Research

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead Sciences beat Q3 earnings expectations with adjusted EPS of $2.55 and revenues of $8.3 billion, driven by strong HIV drug sales (up 18% to $6.25 billion) led by Biktarvy, Descovy, and Yeztugo. Trodelvy oncology sales jumped 42% and Livdelzi grew 93%, prompting the company to raise 2026 product sales guidance to $31-$31.3 billion. However, Cell Therapy revenues declined 18% amid competitive pressures, and the company faces a $1.5 billion revenue headwind for Biktarvy in 2028 from Medicare pricing changes.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.